The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015-2020 : implications for novel national recommendations

Author

  • Maria Pissa
  • Teo Helkkula
  • Frida Appelqvist
  • Gustav Silander
  • Åke Borg
  • Jenny Pettersson
  • Jan Lapins
  • Kari Nielsen
  • Veronica Höiom
  • Hildur Helgadottir

Summary, in English

Background: Inherited pathogenic variants (PVs) in the CDKN2A gene are among the strongest known risk factors for cutaneous melanoma. Carriers are at high risks to develop multiple primary melanomas and other cancers, in particular pancreatic cancer. In this study, the CDKN2A testing, carried out in Sweden in the years 2015-2020, was evaluated.Materials and methods: Included families had (1) three or more cases of melanoma and/or pancreatic cancer, (2) two melanomas in first-degree relatives, the youngest case <55 years or (3) individuals with three or more multiple primary melanomas, the first before the age of 55 years, and no other affected family members. The included families had at least one affected member that had been tested for CDKN2A PVs.Results: In total, 403 families were included, whereof 913 family members had been diagnosed with cutaneous melanoma and 129 with pancreatic cancer, 33 (8.2%) were found to have PVs in CDKN2A. Frequencies ranged from 0.9% in families with only two melanomas to 43.2% in families with three or more melanoma cases and pancreatic cancer (p < 0.001). The frequency of PVs ranged from 2.1% to 16.5% in families where the youngest case was ≥55 years or <35 years (p = 0.040). In families with or without CDKN2A PVs, 37.6% and 10.0% had melanoma cases that had died from melanoma, respectively (p < 0.001).Discussion: Significant differences were seen in the frequencies of CDKN2A PVs, dependent on numbers or age at diagnosis of melanomas and diagnoses of pancreatic cancers in the family. Further, melanoma cases belonging to families that tested positive for CDKN2A PVs had a significantly higher mortality. To summarize, the current evaluation shows that, with adequately selected criteria to guide genetic testing, CDKN2A PVs are identified at significant frequencies. Identification of carrier families is of importance to ensure that members are enrolled in a preventive surveillance program.

Department/s

  • LUCC: Lund University Cancer Centre
  • Dermatology and Venereology (Lund)
  • Department of Clinical Sciences, Lund
  • LUSCaR- Lund University Skin Cancer Research group

Publishing year

2021-05-04

Language

English

Pages

888-896

Publication/Series

Acta oncologica (Stockholm, Sweden)

Volume

60

Issue

7

Document type

Journal article

Publisher

Taylor & Francis

Topic

  • Cancer and Oncology

Status

Published

Research group

  • LUSCaR- Lund University Skin Cancer Research group

ISBN/ISSN/Other

  • ISSN: 1651-226X